Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  nilotinib
Find trials that include:  Any drugs shown
Results 1-14 of 14 for your search:
Start Over
Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study
Phase: Phase IV
Type: Treatment
Age: Not specified
Trial IDs: CAMN107A2409, NCI-2013-02332, 2012-003902-28, NCT01735955
Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD)
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2012-0697, NCI-2013-00551, NCT01751425
Nilotinib and Binimetinib in Treating Patients with Refractory or Advanced Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Leukemia
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2014-0128, NCI-2015-00044, NCT02225574
Nilotinib in Treating Patients with Early Chronic Phase Chronic Myelogenous Leukemia
Phase: Phase II
Type: Treatment
Age: 16 and over
Trial IDs: 2005-0048, NCI-2012-01313, NCT00129740
Nilotinib in Treating Patients with Recurrent Glioblastoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 091728, NCI-2010-01839, NCT01140568
Nilotinib in Treating Patients With Relapsed or Metastatic Diffuse Giant Cell Tumor of Bone That Cannot Be Removed By Surgery
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-179, NCI-2010-02207, NCT01207492
Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 to 69
Trial IDs: 7195, NCI-2012-01084, CA180-392, NCT01620216
Daunorubicin Hydrochloride, Cytarabine, and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1284, NCI-2013-00469, 12-006178, NCT01806571
Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and under
Trial IDs: CAMN107A2203, NCI-2014-01948, NCT01844765
A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and under
Trial IDs: CAMN107A2120, NCI-2012-01004, 2010-018419-14, NCT01077544
Nilotinib and External Beam Radiation Therapy in Treating Patients with High-Risk Chordoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-072, NCI-2011-03064, CAMN107YUS32T, NCT01407198
Ruxolitinib Phosphate and Nilotinib in Treating Patients with Chronic Myelogenous Leukemia
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: MCC-17114, NCI-2013-00558, 12.09.0004, NCT01702064
Nilotinib and Paclitaxel in Treating Patients with Refractory Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-C-0086, NCI-2014-00688, 150086, P141524, 9659, NCT02379416
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Phase: No phase specified
Type: Health services research, Natural history/Epidemiology
Age: 18 and over
Trial IDs: CA180-330, NCI-2013-02015, NCT01244750
Start Over